Leading explanation: ZR‑75‑1’s exceptional sensitivity to ASH1L knockout can be traced to an epigenetically brittle luminal state in which ASH1L’s H3K36me2 at promoters and enhancers keeps PRC2/EZH2‑mediated H3K27me3 at bay and sustains lineage programs governed by TRPS1 and ER. When ASH1L is removed, PRC2 can spread into active chromatin and repress lineage‑specific transcription, collapsing the luminal transcriptional network. The cell’s chromatin landscape is supported by other chromatin writers (ASF1B, BRPF1) that are themselves top dependencies, suggesting a coordinated chromatin‑activation program that ASH1L helps maintain. In addition, mutations in the MLL/COMPASS axis (e.g., MEN1 frameshift, WDR5 and KMT2B variants) likely weaken H3K4‑mediated activation, increasing dependence on ASH1L’s H3K36me2 to sustain transcription. Thus, ASH1L acts as a keystone for maintaining an open, PRC2‑resistant lineage program in ZR‑75‑1, and its loss triggers a collapse of the transcriptional circuitry.

Second paragraph: There are additional, supportive factors that could contribute but are not as strong as the primary mechanism. The same luminal lineage circuitry centered around TRPS1 and ER is likely vulnerable to chromatin disruption, so any perturbation that destabilizes open chromatin worsens ASH1L dependency. BRPF1 and ASF1B co‑dependence suggests the cell relies on multiple chromatin writers and assembly factors; perturbing one node can amplify the effect of ASH1L loss. Mutations in MEN1, WDR5, and KMT2B could weaken complementary H3K4 activation networks, indirectly increasing reliance on ASH1L’s H3K36me2 to sustain transcription. Even the ASH1L E515K variant, though not well characterized, could leave a residual activity that maintains viability until ASH1L is knocked out, intensifying selective pressure. Collectively, these contextual factors tune the severity of ASH1L dependence rather than acting as independent primary drivers.

Third paragraph: Other interesting facts emerge from the model and data. ASH1L’s catalytic activity is concentrated at regulatory elements of developmentally relevant genes, helping explain why lineage regulators are especially vulnerable. The link between ASH1L, LEDGF, and MLL targets provides a mechanism that could extend beyond leukemia to luminal breast contexts. The co‑dependence on ASF1B and BRPF1 suggests a coordinated chromatin‑activation network where loss of one writer or chaperone can sensitize cells to ASH1L loss. Finally, the model yields testable predictions, such as rescuing with catalytically active ASH1L or using EZH2 inhibitors to mitigate lethality, which could guide experiments and potential therapies.